Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This was a multi-center, randomized, masked, parallel-group, controlled study in patients
with diabetic macular edema, comparing RetisertTM (0.59 mg) with control therapy (standard of
care (SOC) - repeat macular grid laser or observation). The objective was to evaluate the
safety and efficacy of the intravitreal fluocinolone acetonide implant in the treatment of
patients with diabetic macular edema.